Main competitors
Add to a list
1m. EPS revision 1m. Revenue rev. 4m. EPS revision 4m. Revenue rev. 1y. EPS revision 1y. Revenue rev. Divergence of Estimates Nbr of analysts
22
26
22
27
24
18
19
19
22
26
21
26
21
15
18
18
17
17
16
Average 21
Weighted average by Cap. 22
Other Pharmaceuticals